Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12408108 | 1.00 | EPHX2 (0.46) | EPHX2CA1CA2L3MBTL1HSD17B10 | |
| Hydrochloric Acid SCHEMBL28783872 | 0.97 | EPHX2 (0.44) | EPHX2CA1CA2L3MBTL1HSD17B10 | |
| SCHEMBL14573046 | 0.87 | EPHX2 (0.38) | EPHX2CA1CA2L3MBTL1HSD17B10 | |
| SCHEMBL11152783 | 0.77 | EPHX2 (0.42) | EPHX2CA1CA2L3MBTL1HSD17B10 | |
| Hydrochloric Acid SCHEMBL11158221 | 0.75 | EPHX2 (0.41) | EPHX2CA1CA2L3MBTL1HSD17B10 | |
| SCHEMBL1072726 | 0.73 | EPHX2 (0.50) | EPHX2CA1CA2L3MBTL1HSD17B10 | |
| SCHEMBL11148891 | 0.73 | EPHX2 (0.50) | EPHX2CA1CA2L3MBTL1HSD17B10 | |
| SCHEMBL14473378 | 0.71 | CYP2C9 (0.42) | EPHX2L3MBTL1HSD17B10CYP2C9 | |
| Adamantane SCHEMBL28289781 | 0.71 | GRIN2D (0.44) | EPHX2CYP2C9ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11156725 | 0.71 | EPHX2 (0.48) | EPHX2CA1CA2L3MBTL1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130143962-A1 | Adamantyl Derivatives as Therapeutic Agents | WOMEN & INFANTS' HOSPITAL OF RHODE ISLAND (US) | 2013-06-06 | — | — | US | claimed |
| US-20260092039-A1 | DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIV BARCELONA (ES) | 2026-04-02 | — | — | US | disclosed |
| EP-4676916-A1 | DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Universitat De Barcelona (ES) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024184305-A1 | DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIVERSITAT DE BARCELONA (ES) | 2024-09-12 | — | — | WO | disclosed |
| US-20240285611-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2024-08-29 | — | — | US | disclosed |
| US-20230354690-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-02 | — | — | US | disclosed |
| WO-2023205778-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| US-11786519-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230203022-A1 | HETEROCYCLE AND GLUTARIMIDE SKELETON-BASED COMPOUND AND APPLICATIONS THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2023-06-01 | — | — | US | disclosed |
| US-5576321-A | ALKOXY-SUBSTITUTED INDOLES | ELI LILLY AND COMPANY (US) | 1996-11-19 | — | — | US | disclosed |
| WO-1996022290-A1 | COMPOUNDS HAVING EFFECTS ON SEROTONIN-RELATED SYSTEMS | ELI LILLY AND COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| EP-0722941-A2 | Compounds having effects on serotonin-related systems | ELI LILLY AND COMPANY (US) | 1996-07-24 | — | — | EP | disclosed |
| EP-0606222-A1 | CYCLIC HEXAPEPTIDES AS TACHYQUININ ANTAGONISTS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) | 1994-07-20 | — | — | EP | disclosed |
| CN-1081676-A | The indoles and the indazole derivatives that are used for the treatment and the prevention of cerebral disorders, their preparation and application | SANKYO CO (JP) | 1994-02-09 | — | — | CN | disclosed |
| WO-1993003059-A1 | CYCLIC HEXAPEPTIDES AS TACHYQUININ ANTAGONISTS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) | 1993-02-18 | — | — | WO | disclosed |
| US-4491671-A | Process for the preparation of N-substituted imido-dicarboxylic acid diaryl esters | BAYER AKTIENGESELLSCHAFT (DE) | 1985-01-01 | — | — | US | disclosed |
| US-4348331-A | FROM THE HYDROCHLORIDE OF A PRIMARY AMINE AND AN ARYL ESTER HALIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1982-09-07 | — | — | US | disclosed |
| EP-0029658-A1 | Salts of dihalo-2-quinoxaline carboxylic acids, their preparation and pharmaceutical formulations containing them | ELI LILLY AND COMPANY (US) | 1981-06-03 | — | — | EP | disclosed |
| US-4252954-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1981-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203022-A1 | HETEROCYCLE AND GLUTARIMIDE SKELETON-BASED COMPOUND AND APPLICATIONS THEREOF | TNF, GCDH, LITAF | EPHX2 2347/4885CA1 1446/4885CA2 1246/4885 |
| US-20130143962-A1 | Adamantyl Derivatives as Therapeutic Agents | MCL1, TOP2A, TP53 | EPHX2 1901/4885CA1 476/4885CA2 2069/4885 |
| US-20240285611-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | EPHX2 3912/4885CA1 1452/4885CA2 3184/4885 |
| US-20230354690-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | NR1D2, NR1D1, NR1H2 | EPHX2 1507/4885CA1 4585/4885CA2 4128/4885 |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | CLK1, CLK2, CLK3 | EPHX2 4541/4885CA1 3437/4885CA2 2956/4885 |
| US-20260092039-A1 | DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE2, BACE1, GLS2 | EPHX2 57/4885CA1 354/4885CA2 433/4885 |
| US-11786519-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | BAX, BCL2, BCL3 | EPHX2 3912/4885CA1 1452/4885CA2 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.